Patients with advanced kidney cancer who received an experimental vaccine after their tumors were removed were still cancer-free years later in a small

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, researchers report.

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the vaccine candidate appeared to be safe and produced a clear immune response in all nine patients at high risk for recurrences of their cancer.

A new vaccine for kidney cancer shows excellent preliminary results. All patients on the trial had no evidence of cancer three years after the pioneering treatment.

Vaccines generated using the cells left over after tumour removal surgery could help to keep patients from redeveloping cancer.

Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer among adults.

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated robust immune response, according to findings of a new study led by HMS researchers at Dana-Farber Cancer Institute.

After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to an experimental, personalized cancer vaccine, researchers reported Feb. 5.

In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.

Groundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses and keeping patients cancer-free for years.